Top Markets
Coin of the day
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Rankning i aktier #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Aktiekurs
$23.57
Senast synkroniserad: 2026-08-20
Marknadsvärde
$51.76M
Förändring (1 dag)
-0.08%
Förändring (1 år)
289.59%
Land
US
Handel Apollomics, Inc. (APLM)

Kategori

Utdelningsavkastning för Apollomics, Inc. (APLM)
Utdelningsavkastningen (TTM) för Apollomics, Inc. (aktiesymbol: APLM) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Apollomics, Inc. (APLM) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
Företag Utdelningsavkastning Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US